 Luisa Mestroni
Concepts (543)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Dilated | 81 | 2022 | 345 | 10.470 |
Why?
| | Cardiomyopathies | 32 | 2022 | 298 | 6.760 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 20 | 2021 | 33 | 5.610 |
Why?
| | Myocytes, Cardiac | 20 | 2022 | 483 | 3.990 |
Why?
| | Arrhythmias, Cardiac | 25 | 2022 | 312 | 3.710 |
Why?
| | Lamin Type A | 13 | 2021 | 37 | 2.860 |
Why?
| | Heart Failure | 25 | 2021 | 1874 | 2.470 |
Why?
| | Mutation | 34 | 2021 | 3421 | 2.040 |
Why?
| | Myocardium | 20 | 2021 | 1084 | 1.860 |
Why?
| | Tissue Engineering | 6 | 2020 | 352 | 1.850 |
Why?
| | Nanotubes, Carbon | 5 | 2020 | 46 | 1.850 |
Why?
| | Cardiomyopathy, Hypertrophic | 12 | 2021 | 117 | 1.830 |
Why?
| | Muscle Proteins | 7 | 2020 | 212 | 1.730 |
Why?
| | Filamins | 4 | 2021 | 20 | 1.550 |
Why?
| | Phenotype | 29 | 2021 | 3010 | 1.540 |
Why?
| | Death, Sudden, Cardiac | 16 | 2021 | 219 | 1.480 |
Why?
| | Genetic Predisposition to Disease | 21 | 2021 | 2406 | 1.460 |
Why?
| | Tissue Scaffolds | 5 | 2020 | 178 | 1.450 |
Why?
| | Genetic Variation | 6 | 2021 | 983 | 1.410 |
Why?
| | Cell Adhesion | 11 | 2021 | 474 | 1.300 |
Why?
| | Genetic Testing | 13 | 2021 | 381 | 1.300 |
Why?
| | Heart | 10 | 2021 | 682 | 1.260 |
Why?
| | Electrocardiography | 16 | 2020 | 656 | 1.240 |
Why?
| | Sarcomeres | 6 | 2021 | 76 | 1.200 |
Why?
| | Connectin | 10 | 2022 | 25 | 1.180 |
Why?
| | Precision Medicine | 5 | 2020 | 304 | 1.120 |
Why?
| | Pharmacogenetics | 5 | 2014 | 168 | 1.060 |
Why?
| | Glycogen Storage Disease Type IIb | 7 | 2021 | 26 | 1.040 |
Why?
| | Fibroblasts | 3 | 2019 | 904 | 1.030 |
Why?
| | Humans | 166 | 2022 | 112249 | 0.980 |
Why?
| | Mutation, Missense | 9 | 2021 | 324 | 0.950 |
Why?
| | Pedigree | 29 | 2021 | 518 | 0.930 |
Why?
| | Heart Ventricles | 13 | 2021 | 732 | 0.920 |
Why?
| | Gold | 3 | 2020 | 105 | 0.920 |
Why?
| | Microscopy, Atomic Force | 10 | 2022 | 134 | 0.810 |
Why?
| | Genetic Therapy | 2 | 2017 | 277 | 0.810 |
Why?
| | Metal Nanoparticles | 2 | 2020 | 78 | 0.770 |
Why?
| | Prognosis | 18 | 2021 | 3532 | 0.740 |
Why?
| | Dystrophin | 10 | 2020 | 33 | 0.730 |
Why?
| | Ventricular Function | 1 | 2017 | 65 | 0.690 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 54 | 0.680 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 6 | 0.680 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 22 | 0.680 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2018 | 170 | 0.660 |
Why?
| | Plakophilins | 3 | 2021 | 5 | 0.640 |
Why?
| | Laminin | 1 | 2016 | 62 | 0.640 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 219 | 0.630 |
Why?
| | Biomimetics | 1 | 2016 | 44 | 0.620 |
Why?
| | Protein Kinases | 4 | 2013 | 338 | 0.600 |
Why?
| | Genetic Heterogeneity | 2 | 2009 | 61 | 0.590 |
Why?
| | Hydrogels | 2 | 2019 | 554 | 0.590 |
Why?
| | Embryonic Stem Cells | 1 | 2016 | 122 | 0.590 |
Why?
| | DNA Mutational Analysis | 11 | 2018 | 420 | 0.590 |
Why?
| | Receptors, Endothelin | 2 | 2014 | 54 | 0.570 |
Why?
| | Receptors, Adrenergic | 1 | 2014 | 29 | 0.560 |
Why?
| | Lysine | 1 | 2016 | 229 | 0.550 |
Why?
| | Registries | 14 | 2021 | 1805 | 0.550 |
Why?
| | Male | 79 | 2022 | 60715 | 0.550 |
Why?
| | Connexin 43 | 1 | 2014 | 29 | 0.540 |
Why?
| | Defibrillators, Implantable | 4 | 2021 | 401 | 0.540 |
Why?
| | Cell Adhesion Molecules | 1 | 2014 | 190 | 0.530 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 215 | 0.530 |
Why?
| | Polymers | 3 | 2020 | 472 | 0.520 |
Why?
| | src-Family Kinases | 1 | 2014 | 96 | 0.520 |
Why?
| | Middle Aged | 50 | 2021 | 28676 | 0.510 |
Why?
| | Cardiovascular Agents | 1 | 2014 | 127 | 0.510 |
Why?
| | Genes, Dominant | 12 | 2007 | 101 | 0.500 |
Why?
| | Echocardiography | 10 | 2021 | 636 | 0.500 |
Why?
| | Cytoskeleton | 7 | 2020 | 171 | 0.500 |
Why?
| | Adult | 55 | 2021 | 31789 | 0.500 |
Why?
| | Female | 75 | 2022 | 62624 | 0.490 |
Why?
| | Animals | 32 | 2021 | 35194 | 0.480 |
Why?
| | Human Genome Project | 1 | 2011 | 16 | 0.460 |
Why?
| | Genetic Association Studies | 5 | 2021 | 409 | 0.460 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1130 | 0.460 |
Why?
| | Rats | 10 | 2021 | 6372 | 0.460 |
Why?
| | Disease Management | 4 | 2021 | 605 | 0.440 |
Why?
| | Valsartan | 2 | 2021 | 19 | 0.440 |
Why?
| | Disease Progression | 5 | 2021 | 2474 | 0.440 |
Why?
| | Myocardial Infarction | 2 | 2019 | 1111 | 0.430 |
Why?
| | Nuclear Proteins | 2 | 2009 | 648 | 0.420 |
Why?
| | Genetic Linkage | 10 | 2001 | 364 | 0.400 |
Why?
| | Gene Expression Regulation | 4 | 2020 | 2628 | 0.400 |
Why?
| | Desmoplakins | 2 | 2020 | 24 | 0.390 |
Why?
| | Risk Assessment | 11 | 2020 | 3137 | 0.390 |
Why?
| | Muscular Dystrophies | 2 | 2018 | 36 | 0.380 |
Why?
| | Genome, Human | 1 | 2011 | 389 | 0.380 |
Why?
| | Italy | 13 | 2020 | 89 | 0.380 |
Why?
| | Cell Differentiation | 2 | 2017 | 1824 | 0.380 |
Why?
| | Desmosomes | 3 | 2019 | 21 | 0.370 |
Why?
| | Molecular Biology | 4 | 1997 | 66 | 0.370 |
Why?
| | Stroke Volume | 9 | 2022 | 515 | 0.370 |
Why?
| | Ventricular Function, Left | 5 | 2022 | 484 | 0.360 |
Why?
| | Chromosome Mapping | 8 | 1997 | 570 | 0.360 |
Why?
| | Ventricular Dysfunction, Left | 5 | 2016 | 388 | 0.350 |
Why?
| | Lamins | 2 | 2004 | 4 | 0.350 |
Why?
| | Cells, Cultured | 9 | 2021 | 4413 | 0.350 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2021 | 189 | 0.350 |
Why?
| | Myosin Heavy Chains | 3 | 2013 | 196 | 0.340 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2020 | 462 | 0.330 |
Why?
| | Heart Transplantation | 7 | 2020 | 694 | 0.310 |
Why?
| | Repressor Proteins | 1 | 2009 | 395 | 0.310 |
Why?
| | Ventricular Myosins | 1 | 2005 | 37 | 0.300 |
Why?
| | Materials Testing | 2 | 2019 | 369 | 0.280 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2004 | 17 | 0.270 |
Why?
| | Fibrosis | 3 | 2021 | 416 | 0.270 |
Why?
| | Heterozygote | 7 | 2021 | 270 | 0.270 |
Why?
| | Desmin | 2 | 2018 | 33 | 0.270 |
Why?
| | X Chromosome | 8 | 2001 | 53 | 0.270 |
Why?
| | Risk Factors | 11 | 2020 | 8978 | 0.260 |
Why?
| | Adolescent | 25 | 2021 | 18577 | 0.260 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2016 | 150 | 0.260 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2021 | 0.260 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 3024 | 0.260 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2004 | 596 | 0.250 |
Why?
| | Genetic Markers | 4 | 2018 | 402 | 0.250 |
Why?
| | Point Mutation | 4 | 2011 | 258 | 0.250 |
Why?
| | Animals, Newborn | 4 | 2020 | 868 | 0.240 |
Why?
| | Tachycardia, Ventricular | 3 | 2008 | 179 | 0.240 |
Why?
| | Chromosomes, Human, Pair 9 | 3 | 1997 | 48 | 0.240 |
Why?
| | Microtechnology | 1 | 2021 | 4 | 0.240 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 20 | 0.230 |
Why?
| | Chagas Disease | 1 | 2021 | 31 | 0.230 |
Why?
| | Heart Murmurs | 1 | 2021 | 13 | 0.230 |
Why?
| | ADAM10 Protein | 1 | 2021 | 31 | 0.220 |
Why?
| | Actinin | 1 | 2020 | 16 | 0.220 |
Why?
| | Genomics | 2 | 2017 | 603 | 0.220 |
Why?
| | Gamma Rays | 1 | 2021 | 53 | 0.220 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 3 | 2017 | 17 | 0.220 |
Why?
| | Neuromuscular Diseases | 1 | 2002 | 97 | 0.220 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 70 | 0.210 |
Why?
| | Epidermolysis Bullosa Simplex | 1 | 2020 | 9 | 0.210 |
Why?
| | Mechanical Phenomena | 1 | 2021 | 86 | 0.210 |
Why?
| | Heart Conduction System | 3 | 2016 | 91 | 0.210 |
Why?
| | Ectodermal Dysplasia | 1 | 2020 | 16 | 0.210 |
Why?
| | Genotype | 4 | 2022 | 2070 | 0.210 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1240 | 0.210 |
Why?
| | Myofibroblasts | 1 | 2021 | 120 | 0.210 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2021 | 73 | 0.210 |
Why?
| | Elastic Modulus | 5 | 2022 | 120 | 0.210 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 42 | 0.200 |
Why?
| | Ankyrins | 1 | 2019 | 7 | 0.200 |
Why?
| | Double-Blind Method | 3 | 2021 | 1670 | 0.200 |
Why?
| | Radiation Injuries | 1 | 2021 | 127 | 0.200 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2018 | 444 | 0.200 |
Why?
| | Elasticity | 2 | 2017 | 205 | 0.200 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 194 | 0.200 |
Why?
| | Nanostructures | 1 | 2020 | 113 | 0.200 |
Why?
| | Muscular Diseases | 1 | 2000 | 102 | 0.200 |
Why?
| | Time Factors | 10 | 2019 | 7054 | 0.200 |
Why?
| | Nanotechnology | 1 | 2020 | 134 | 0.200 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 168 | 0.190 |
Why?
| | Actin Cytoskeleton | 2 | 2021 | 88 | 0.190 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 231 | 0.190 |
Why?
| | Gene Deletion | 2 | 1997 | 387 | 0.190 |
Why?
| | Atrial Fibrillation | 1 | 2003 | 353 | 0.190 |
Why?
| | Cytochalasin D | 2 | 2015 | 6 | 0.190 |
Why?
| | Coculture Techniques | 1 | 2019 | 212 | 0.190 |
Why?
| | Immunity, Cellular | 2 | 2018 | 308 | 0.190 |
Why?
| | Mice | 11 | 2021 | 15510 | 0.190 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 187 | 0.190 |
Why?
| | Aged | 24 | 2022 | 20025 | 0.180 |
Why?
| | Alleles | 1 | 2021 | 905 | 0.180 |
Why?
| | Membrane Proteins | 2 | 2021 | 1091 | 0.180 |
Why?
| | Sodium Channels | 2 | 2011 | 77 | 0.180 |
Why?
| | Cell Nucleus | 3 | 2019 | 623 | 0.180 |
Why?
| | Intermediate Filaments | 1 | 2017 | 38 | 0.180 |
Why?
| | Skin Physiological Phenomena | 1 | 2017 | 33 | 0.180 |
Why?
| | Cardiac Imaging Techniques | 1 | 2017 | 20 | 0.180 |
Why?
| | Family Health | 2 | 2011 | 209 | 0.180 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 140 | 0.180 |
Why?
| | Gelatin | 1 | 2017 | 35 | 0.180 |
Why?
| | DNA | 2 | 2016 | 1405 | 0.180 |
Why?
| | Ion Channels | 1 | 2018 | 127 | 0.170 |
Why?
| | Myocardial Contraction | 3 | 2018 | 387 | 0.170 |
Why?
| | Retrospective Studies | 11 | 2021 | 11118 | 0.170 |
Why?
| | Muscle, Skeletal | 6 | 2005 | 1406 | 0.170 |
Why?
| | Contrast Media | 1 | 2021 | 405 | 0.170 |
Why?
| | Transcriptome | 2 | 2020 | 680 | 0.170 |
Why?
| | Extracellular Matrix | 1 | 2021 | 421 | 0.170 |
Why?
| | Mechanotransduction, Cellular | 1 | 2018 | 92 | 0.170 |
Why?
| | Troponin T | 2 | 2013 | 41 | 0.170 |
Why?
| | Young Adult | 10 | 2021 | 10899 | 0.170 |
Why?
| | Internationality | 1 | 2017 | 150 | 0.170 |
Why?
| | Vasodilator Agents | 4 | 1988 | 323 | 0.160 |
Why?
| | Cross-Sectional Studies | 4 | 2019 | 4207 | 0.160 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 95 | 0.160 |
Why?
| | Prevalence | 8 | 2021 | 2383 | 0.160 |
Why?
| | Shear Strength | 1 | 2016 | 64 | 0.160 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 309 | 0.160 |
Why?
| | MicroRNAs | 2 | 2020 | 626 | 0.160 |
Why?
| | Exome | 2 | 2017 | 210 | 0.160 |
Why?
| | Odds Ratio | 2 | 2017 | 1061 | 0.160 |
Why?
| | Keratinocytes | 1 | 2017 | 235 | 0.160 |
Why?
| | Multigene Family | 1 | 2017 | 220 | 0.160 |
Why?
| | DNA Damage | 1 | 2019 | 371 | 0.160 |
Why?
| | Chromosomes, Human, Pair 14 | 4 | 1996 | 22 | 0.160 |
Why?
| | Wolff-Parkinson-White Syndrome | 1 | 2016 | 24 | 0.160 |
Why?
| | Nanofibers | 1 | 2015 | 22 | 0.160 |
Why?
| | Treatment Failure | 1 | 2017 | 327 | 0.160 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 352 | 0.150 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1599 | 0.150 |
Why?
| | Cell Proliferation | 4 | 2021 | 2400 | 0.150 |
Why?
| | Polyesters | 1 | 2015 | 68 | 0.150 |
Why?
| | Chromosomes | 1 | 1995 | 87 | 0.150 |
Why?
| | Lysosome-Associated Membrane Glycoproteins | 3 | 2016 | 23 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2009 | 366 | 0.140 |
Why?
| | Genotyping Techniques | 2 | 2012 | 84 | 0.140 |
Why?
| | DNA Methylation | 1 | 2019 | 436 | 0.140 |
Why?
| | Biopsy | 3 | 2017 | 1064 | 0.140 |
Why?
| | Spectrum Analysis | 1 | 2015 | 96 | 0.140 |
Why?
| | Electrocardiography, Ambulatory | 3 | 2015 | 67 | 0.140 |
Why?
| | Heart Aneurysm | 1 | 1994 | 12 | 0.140 |
Why?
| | Catheter Ablation | 2 | 2014 | 312 | 0.140 |
Why?
| | Propanolamines | 2 | 2009 | 116 | 0.140 |
Why?
| | Follow-Up Studies | 13 | 2021 | 4887 | 0.130 |
Why?
| | Logistic Models | 2 | 2017 | 2049 | 0.130 |
Why?
| | Cell Membrane | 1 | 2018 | 770 | 0.130 |
Why?
| | Cell Enlargement | 1 | 2013 | 7 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2016 | 361 | 0.130 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2013 | 16 | 0.130 |
Why?
| | DNA, Mitochondrial | 3 | 2004 | 200 | 0.130 |
Why?
| | Genetics | 1 | 2013 | 35 | 0.130 |
Why?
| | Giant Cells | 1 | 2013 | 22 | 0.130 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 218 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 735 | 0.130 |
Why?
| | Polymerase Chain Reaction | 7 | 2008 | 1099 | 0.130 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 47 | 0.130 |
Why?
| | Atrioventricular Block | 1 | 2013 | 44 | 0.130 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 133 | 0.130 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2013 | 112 | 0.120 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 3120 | 0.120 |
Why?
| | Action Potentials | 1 | 2016 | 452 | 0.120 |
Why?
| | Monitoring, Physiologic | 2 | 2021 | 276 | 0.120 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2228 | 0.120 |
Why?
| | American Heart Association | 1 | 2013 | 278 | 0.120 |
Why?
| | Heart Rate | 2 | 2016 | 842 | 0.120 |
Why?
| | Autophagy | 1 | 2016 | 307 | 0.120 |
Why?
| | Nuclear Lamina | 2 | 2020 | 10 | 0.120 |
Why?
| | Electrophysiological Phenomena | 1 | 2012 | 52 | 0.120 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2021 | 148 | 0.120 |
Why?
| | Surface Properties | 1 | 2013 | 430 | 0.120 |
Why?
| | Penetrance | 1 | 2011 | 27 | 0.120 |
Why?
| | Sex Chromosome Aberrations | 3 | 1997 | 42 | 0.120 |
Why?
| | Chromosome Disorders | 3 | 1997 | 42 | 0.120 |
Why?
| | Particle Size | 1 | 2013 | 404 | 0.110 |
Why?
| | Survival Rate | 6 | 2021 | 1851 | 0.110 |
Why?
| | Child | 14 | 2019 | 17357 | 0.110 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2014 | 400 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 4 | 2015 | 873 | 0.110 |
Why?
| | Graft Rejection | 2 | 2004 | 567 | 0.110 |
Why?
| | Equipment Design | 1 | 2013 | 530 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2012 | 797 | 0.110 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1641 | 0.110 |
Why?
| | Chromosome Aberrations | 3 | 1997 | 145 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 4 | 2021 | 3017 | 0.110 |
Why?
| | Sarcoidosis | 1 | 2012 | 125 | 0.110 |
Why?
| | Syndrome | 1 | 2011 | 342 | 0.110 |
Why?
| | Sensitivity and Specificity | 6 | 2015 | 1926 | 0.110 |
Why?
| | Robotics | 1 | 2011 | 77 | 0.110 |
Why?
| | Family | 2 | 2014 | 569 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2004 | 673 | 0.100 |
Why?
| | Nanoparticles | 1 | 2014 | 337 | 0.100 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1430 | 0.100 |
Why?
| | Genetic Counseling | 2 | 2009 | 66 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 1 | 2014 | 474 | 0.100 |
Why?
| | Chromosomes, Human, Pair 3 | 3 | 2004 | 58 | 0.100 |
Why?
| | Cell Division | 1 | 2012 | 880 | 0.100 |
Why?
| | Gene Frequency | 3 | 2017 | 569 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2015 | 1526 | 0.100 |
Why?
| | Sequence Deletion | 3 | 2014 | 191 | 0.100 |
Why?
| | United States | 8 | 2021 | 12170 | 0.100 |
Why?
| | Enterovirus | 3 | 1994 | 70 | 0.100 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 5232 | 0.100 |
Why?
| | Disease-Free Survival | 3 | 2015 | 681 | 0.100 |
Why?
| | Global Health | 2 | 2014 | 338 | 0.090 |
Why?
| | Cardiomyopathy, Restrictive | 4 | 1999 | 8 | 0.090 |
Why?
| | Cohort Studies | 6 | 2020 | 4937 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1828 | 0.090 |
Why?
| | Organic Cation Transport Proteins | 1 | 2008 | 37 | 0.090 |
Why?
| | Prospective Studies | 8 | 2018 | 6167 | 0.090 |
Why?
| | Carnitine | 1 | 2008 | 67 | 0.090 |
Why?
| | Amiodarone | 4 | 2011 | 25 | 0.090 |
Why?
| | Biomarkers | 1 | 2018 | 3464 | 0.090 |
Why?
| | Endothelin-1 | 1 | 2009 | 166 | 0.090 |
Why?
| | Consensus | 2 | 2019 | 412 | 0.090 |
Why?
| | Myocarditis | 4 | 1998 | 86 | 0.080 |
Why?
| | Endocardium | 3 | 1999 | 35 | 0.080 |
Why?
| | Retinitis Pigmentosa | 1 | 2006 | 15 | 0.080 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 1997 | 75 | 0.080 |
Why?
| | Myopia | 1 | 2006 | 30 | 0.080 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 3 | 2014 | 31 | 0.080 |
Why?
| | Europe | 2 | 2018 | 348 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2021 | 3892 | 0.080 |
Why?
| | Child, Preschool | 6 | 2017 | 9655 | 0.080 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 63 | 0.070 |
Why?
| | Autoimmune Diseases | 3 | 2001 | 432 | 0.070 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 177 | 0.070 |
Why?
| | Conserved Sequence | 1 | 2005 | 226 | 0.070 |
Why?
| | Gene Expression | 3 | 2008 | 1578 | 0.070 |
Why?
| | Virus Diseases | 3 | 1998 | 181 | 0.070 |
Why?
| | Cataract | 1 | 2006 | 143 | 0.070 |
Why?
| | NIH 3T3 Cells | 2 | 2015 | 133 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2018 | 3353 | 0.070 |
Why?
| | Homozygote | 2 | 2015 | 202 | 0.070 |
Why?
| | Cell Shape | 2 | 2015 | 58 | 0.070 |
Why?
| | Hemodynamics | 9 | 1992 | 1097 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2013 | 6778 | 0.070 |
Why?
| | Treatment Outcome | 5 | 2021 | 8944 | 0.070 |
Why?
| | Biomechanical Phenomena | 2 | 2018 | 665 | 0.070 |
Why?
| | Primary Prevention | 2 | 2016 | 214 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 309 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 485 | 0.060 |
Why?
| | Haplotypes | 3 | 2013 | 548 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1002 | 0.060 |
Why?
| | Antigens, CD | 2 | 2017 | 507 | 0.060 |
Why?
| | Mass Screening | 1 | 2010 | 1038 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 1695 | 0.060 |
Why?
| | Genetic Background | 1 | 2021 | 8 | 0.060 |
Why?
| | Optical Tweezers | 1 | 2021 | 22 | 0.060 |
Why?
| | Metoprolol | 2 | 1999 | 44 | 0.060 |
Why?
| | RNA | 2 | 2019 | 769 | 0.060 |
Why?
| | Nanotubes | 1 | 2021 | 45 | 0.060 |
Why?
| | Ephrin-B2 | 1 | 2021 | 38 | 0.060 |
Why?
| | Electric Conductivity | 1 | 2020 | 98 | 0.050 |
Why?
| | Ferric Compounds | 1 | 2020 | 38 | 0.050 |
Why?
| | Gadolinium | 1 | 2021 | 79 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2020 | 2847 | 0.050 |
Why?
| | Exercise Test | 4 | 2017 | 592 | 0.050 |
Why?
| | Models, Biological | 2 | 2021 | 1843 | 0.050 |
Why?
| | Denmark | 1 | 2019 | 30 | 0.050 |
Why?
| | Base Sequence | 5 | 2014 | 2323 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 3013 | 0.050 |
Why?
| | Transfection | 2 | 2017 | 996 | 0.050 |
Why?
| | RNA, Viral | 2 | 1994 | 589 | 0.050 |
Why?
| | Brazil | 1 | 2019 | 107 | 0.050 |
Why?
| | Computational Biology | 2 | 2015 | 666 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 440 | 0.050 |
Why?
| | Maleimides | 1 | 2019 | 32 | 0.050 |
Why?
| | Cell Plasticity | 1 | 2019 | 25 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 640 | 0.050 |
Why?
| | Apoptosis | 2 | 2021 | 2662 | 0.050 |
Why?
| | Principal Component Analysis | 1 | 2020 | 183 | 0.050 |
Why?
| | E2F Transcription Factors | 1 | 2019 | 60 | 0.050 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2019 | 41 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2020 | 314 | 0.050 |
Why?
| | CpG Islands | 1 | 2019 | 107 | 0.050 |
Why?
| | Heterochromatin | 1 | 2019 | 36 | 0.050 |
Why?
| | Carbazoles | 1 | 1999 | 88 | 0.050 |
Why?
| | Infant | 4 | 2020 | 8024 | 0.050 |
Why?
| | Canada | 1 | 2019 | 330 | 0.050 |
Why?
| | Regeneration | 1 | 2020 | 184 | 0.050 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2018 | 16 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 175 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 1041 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2020 | 491 | 0.050 |
Why?
| | Alginates | 1 | 2018 | 46 | 0.050 |
Why?
| | Intercellular Junctions | 1 | 2017 | 31 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2013 | 1130 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 787 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2021 | 2877 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1456 | 0.040 |
Why?
| | beta Catenin | 1 | 2019 | 228 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 448 | 0.040 |
Why?
| | Multilevel Analysis | 1 | 2017 | 30 | 0.040 |
Why?
| | Netherlands | 1 | 2017 | 70 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 314 | 0.040 |
Why?
| | Aorta | 1 | 2000 | 404 | 0.040 |
Why?
| | Age Factors | 2 | 2016 | 3330 | 0.040 |
Why?
| | Ultrasonography | 2 | 1999 | 764 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 576 | 0.040 |
Why?
| | Bundle-Branch Block | 1 | 2016 | 27 | 0.040 |
Why?
| | Indoles | 1 | 2019 | 356 | 0.040 |
Why?
| | Biocompatible Materials | 1 | 2020 | 377 | 0.040 |
Why?
| | Gene Editing | 1 | 2017 | 63 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2018 | 217 | 0.040 |
Why?
| | Incidence | 3 | 2011 | 2453 | 0.040 |
Why?
| | Heredity | 1 | 2015 | 18 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 853 | 0.040 |
Why?
| | Membrane Potentials | 1 | 2017 | 268 | 0.040 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 82 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2017 | 153 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2029 | 0.040 |
Why?
| | Lod Score | 1 | 1995 | 77 | 0.040 |
Why?
| | Cell Movement | 1 | 2021 | 930 | 0.040 |
Why?
| | Sodium | 1 | 2017 | 203 | 0.040 |
Why?
| | Genes, Recessive | 1 | 1995 | 76 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2017 | 204 | 0.040 |
Why?
| | Recovery of Function | 1 | 2019 | 603 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 572 | 0.040 |
Why?
| | Cadherins | 1 | 2017 | 188 | 0.040 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2015 | 217 | 0.040 |
Why?
| | Pregnancy | 2 | 2006 | 5185 | 0.040 |
Why?
| | Exons | 2 | 2008 | 316 | 0.040 |
Why?
| | Signal Transduction | 2 | 2020 | 4914 | 0.040 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1995 | 124 | 0.040 |
Why?
| | Enterovirus Infections | 2 | 1994 | 146 | 0.040 |
Why?
| | Introns | 1 | 1996 | 242 | 0.040 |
Why?
| | Genes, Immunoglobulin | 1 | 1994 | 36 | 0.040 |
Why?
| | Mutagenesis | 1 | 2015 | 185 | 0.040 |
Why?
| | Cytochalasins | 1 | 2014 | 3 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2015 | 105 | 0.040 |
Why?
| | Viscosity | 1 | 2015 | 109 | 0.040 |
Why?
| | RNA Splicing | 1 | 1996 | 243 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 662 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 129 | 0.030 |
Why?
| | Turner Syndrome | 1 | 1994 | 32 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 255 | 0.030 |
Why?
| | Major Histocompatibility Complex | 1 | 1994 | 230 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 120 | 0.030 |
Why?
| | Cardiac Myosins | 1 | 2013 | 30 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 417 | 0.030 |
Why?
| | Body Temperature | 1 | 2014 | 280 | 0.030 |
Why?
| | Cause of Death | 1 | 2015 | 382 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1994 | 102 | 0.030 |
Why?
| | Ventricular Fibrillation | 1 | 2013 | 61 | 0.030 |
Why?
| | Formaldehyde | 1 | 2013 | 54 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 1994 | 212 | 0.030 |
Why?
| | Electrophysiology | 1 | 2013 | 227 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 494 | 0.030 |
Why?
| | Skin | 1 | 2017 | 694 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 2012 | 19 | 0.030 |
Why?
| | Mediastinal Diseases | 1 | 2012 | 10 | 0.030 |
Why?
| | Pacemaker, Artificial | 1 | 2013 | 116 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2888 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1243 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2817 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1185 | 0.030 |
Why?
| | Cattle | 1 | 2014 | 976 | 0.030 |
Why?
| | Patient Selection | 1 | 2015 | 692 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1992 | 159 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1108 | 0.030 |
Why?
| | Blood Pressure | 2 | 2016 | 1755 | 0.030 |
Why?
| | Immune System | 1 | 1992 | 198 | 0.030 |
Why?
| | Antibody Formation | 1 | 1992 | 299 | 0.030 |
Why?
| | Observer Variation | 1 | 2011 | 333 | 0.030 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2009 | 11 | 0.020 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2009 | 22 | 0.020 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 999 | 0.020 |
Why?
| | Metalloendopeptidases | 1 | 2009 | 64 | 0.020 |
Why?
| | Endothelins | 1 | 2009 | 62 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2010 | 246 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2013 | 820 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 2919 | 0.020 |
Why?
| | Solute Carrier Family 22 Member 5 | 1 | 2008 | 5 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 1988 | 123 | 0.020 |
Why?
| | Autoimmunity | 1 | 1994 | 771 | 0.020 |
Why?
| | Cricetulus | 1 | 2008 | 107 | 0.020 |
Why?
| | Death, Sudden | 1 | 1987 | 29 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2009 | 330 | 0.020 |
Why?
| | CHO Cells | 1 | 2008 | 160 | 0.020 |
Why?
| | Amyloidosis | 1 | 1987 | 41 | 0.020 |
Why?
| | Cricetinae | 1 | 2008 | 293 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2007 | 30 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2006 | 29 | 0.020 |
Why?
| | Electroretinography | 1 | 2006 | 41 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 34 | 0.020 |
Why?
| | Visual Fields | 1 | 2006 | 81 | 0.020 |
Why?
| | Algorithms | 1 | 2013 | 1548 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2006 | 109 | 0.020 |
Why?
| | Models, Genetic | 1 | 2009 | 659 | 0.020 |
Why?
| | Terminology as Topic | 2 | 1999 | 227 | 0.020 |
Why?
| | Antimetabolites | 1 | 2004 | 27 | 0.020 |
Why?
| | Growth Inhibitors | 1 | 2004 | 54 | 0.020 |
Why?
| | Coxsackievirus Infections | 1 | 1984 | 16 | 0.020 |
Why?
| | Azathioprine | 1 | 2004 | 50 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2007 | 446 | 0.020 |
Why?
| | Everolimus | 1 | 2004 | 57 | 0.020 |
Why?
| | Calcineurin Inhibitors | 1 | 2004 | 64 | 0.020 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 77 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 764 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2005 | 348 | 0.020 |
Why?
| | Cyclosporine | 1 | 2004 | 185 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2005 | 344 | 0.020 |
Why?
| | Tacrolimus | 1 | 2004 | 143 | 0.020 |
Why?
| | Sirolimus | 1 | 2004 | 181 | 0.020 |
Why?
| | Captopril | 1 | 1983 | 17 | 0.020 |
Why?
| | Colorado | 1 | 2013 | 4552 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 908 | 0.020 |
Why?
| | Comorbidity | 1 | 2008 | 1597 | 0.020 |
Why?
| | Proline | 1 | 1983 | 74 | 0.020 |
Why?
| | Administration, Oral | 1 | 2004 | 800 | 0.010 |
Why?
| | Probability | 1 | 2003 | 339 | 0.010 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 352 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 463 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 489 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 1992 | 1651 | 0.010 |
Why?
| | Risk | 1 | 2003 | 944 | 0.010 |
Why?
| | Enterovirus B, Human | 2 | 1993 | 26 | 0.010 |
Why?
| | Chronic Disease | 1 | 1985 | 1666 | 0.010 |
Why?
| | Echocardiography, Doppler | 1 | 1999 | 128 | 0.010 |
Why?
| | World Health Organization | 1 | 1998 | 111 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 228 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1999 | 481 | 0.010 |
Why?
| | Survival Analysis | 2 | 1991 | 1414 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1999 | 663 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1995 | 85 | 0.010 |
Why?
| | Receptors, Interleukin | 1 | 1994 | 50 | 0.010 |
Why?
| | Organ Specificity | 1 | 1995 | 310 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1994 | 45 | 0.010 |
Why?
| | Gene Amplification | 1 | 1994 | 107 | 0.010 |
Why?
| | Fathers | 1 | 1994 | 46 | 0.010 |
Why?
| | Genome, Viral | 1 | 1994 | 141 | 0.010 |
Why?
| | Virology | 1 | 1993 | 22 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 170 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1993 | 226 | 0.010 |
Why?
| | Interleukins | 1 | 1994 | 235 | 0.010 |
Why?
| | Iodocyanopindolol | 1 | 1992 | 14 | 0.010 |
Why?
| | Pindolol | 1 | 1992 | 18 | 0.010 |
Why?
| | Neuropeptide Y | 1 | 1992 | 15 | 0.010 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1992 | 45 | 0.010 |
Why?
| | Catecholamines | 1 | 1992 | 117 | 0.010 |
Why?
| | Complement System Proteins | 1 | 1994 | 267 | 0.010 |
Why?
| | Isoproterenol | 1 | 1992 | 155 | 0.010 |
Why?
| | Adenylyl Cyclases | 1 | 1992 | 159 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 649 | 0.010 |
Why?
| | Autoantigens | 1 | 1994 | 411 | 0.010 |
Why?
| | DNA, Viral | 1 | 1993 | 442 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1260 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1994 | 606 | 0.010 |
Why?
| | Felodipine | 1 | 1988 | 3 | 0.010 |
Why?
| | Nitrendipine | 1 | 1988 | 13 | 0.010 |
Why?
| | Nicardipine | 1 | 1988 | 6 | 0.010 |
Why?
| | Nisoldipine | 1 | 1988 | 10 | 0.010 |
Why?
| | Diltiazem | 1 | 1988 | 21 | 0.010 |
Why?
| | Verapamil | 1 | 1988 | 34 | 0.010 |
Why?
| | Nifedipine | 1 | 1988 | 32 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1999 | 5017 | 0.010 |
Why?
| | Quality of Life | 1 | 1999 | 2089 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1989 | 365 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1995 | 1473 | 0.010 |
Why?
| | Autoantibodies | 1 | 1994 | 1208 | 0.010 |
Why?
| | Cardiomyopathy, Alcoholic | 1 | 1985 | 1 | 0.000 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1985 | 76 | 0.000 |
Why?
| | Heart Septal Defects | 1 | 1984 | 11 | 0.000 |
Why?
| | Physical Exertion | 1 | 1986 | 250 | 0.000 |
Why?
| | Cardiac Output | 1 | 1984 | 159 | 0.000 |
Why?
| | Cardiac Catheterization | 1 | 1987 | 545 | 0.000 |
Why?
| | Vascular Resistance | 1 | 1984 | 397 | 0.000 |
Why?
| | Coronary Disease | 1 | 1984 | 469 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1984 | 512 | 0.000 |
Why?
| | Ethanol | 1 | 1985 | 705 | 0.000 |
Why?
| | Hypertension | 1 | 1985 | 1166 | 0.000 |
Why?
|
|
Mestroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|